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Summary  Functional  magnetic  resonance  imaging  (MRI)  improves  tissue  characterisation  and
staging of  bone  and  soft-tissue  tumours  compared  to  the  information  usually  supplied  by  struc-
tural imaging.  Perfusion  MRI,  diffusion  MRI,  and  in-phase/opposed-phase  MRI  can  be  performed
in everyday  practice.  Nuclear  magnetic  resonance  (NMR)  spectroscopic  imaging  is  a  challenging
technique  that  is  available  only  in  specialised  centres.  Tumour  characterisation  can  beneﬁt  from
perfusion MRI  with  dynamic  gadolinium  injection  and  enhancement  time-intensity  curve  analy-
sis or  from  diffusion  MRI.  Highly  cellular  malignant  tumours  restrict  diffusion  and  consequently
decrease the  apparent  diffusion  coefﬁcient  (ADC).  With  some  tumours,  tissue  heterogeneity
or the  presence  of  a  myxoid  component  can  hinder  this  evaluation.  Chronic  hematoma  can  be
distinguished  from  haemorrhagic  sarcoma.  Perfusion  and  diffusion  MRI  contribute  to  the  eval-
uation of  tumour  spread,  in  particular  by  differentiating  oedema  from  tumour  tissue.  Another
advantage  of  perfusion  MRI  and  ADC  mapping  is  the  early  identiﬁcation  of  good  responders  to
chemotherapy.  The  use  of  NMR  spectroscopy  remains  limited.  Evaluation  of  the  choline  peak
can help  to  differentiate  benign  and  malignant  tumours.  All  available  functional  MRI  techniques
have limitations  and  leave  some  overlap  between  benign  and  malignant  tumours.  Functional
MRI can  be  used  only  as  an  adjunctive  imaging  modality  to  complement  morphological  imaging.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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tIntroduction
Magnetic  resonance  imaging  (MRI)  is  now  indispensable
for  the  preoperative  workup  and  therapeutic  follow-up  of
patients  with  musculoskeletal  tumours  [1,2]. Standard  MRI
uses  structural  criteria  to  assess  tumour  spread  to  the  bone
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http://dx.doi.org/10.1016/j.otsr.2012.12.005r  soft  tissues  but  makes  only  a  limited  contribution  to
he  differentiation  of  benign  and  malignant  tumours  and
o  the  characterisation  of  the  tumour  tissue  [2,3]. Among
ther  imaging  tools,  the  most  speciﬁc  for  determining  that
he  lesion  is  neoplastic  is  radiography,  which  determines
hether  MRI  is  in  order  [1].  In  many  patients,  standard  MRI
annot  determine  the  exact  extent  of  tumour  necrosis  or
he  presence  of  viable  tumour  cells,  two  criteria  used  to
valuate  the  treatment  response  and  predict  the  outcome
2,4].  Patients  in  this  situation  can  beneﬁt  from  the  latest
served.
S116  J.-L.  Drapé
Figure  1  The  various  types  of  MRI  enhancement  time-intensity  curves  after  gadolinium  injection.
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•dvances  in  MRI  such  as  perfusion  imaging,  proton  nuclear
agnetic  resonance  (NMR)  spectroscopy,  diffusion  imaging,
nd  in-phase/opposed-phase  imaging  [2].
erfusion imaging by dynamic contrast-agent
njection
ynamic  perfusion  MRI  is  a  functional  imaging  technique
n  which  early  enhancement  of  the  tumour  is  monitored
fter  an  intravenous  gadolinium  bolus  injection  [5].  This
echnique  provides  information  on  vascularisation  and  per-
usion,  capillary  permeability,  and  interstitial  compartment
olume  [1,5]. It  is  often  used  to  evaluate  musculoskeletal
umours  [6—8]. The  main  contributions  of  dynamic  perfusion
RI  are  identiﬁcation  of  viable  tumour  sites  to  guide  the
iopsy,  monitoring  of  preoperative  chemotherapy,  and  dif-
erentiation  of  residual  tumour  from  scarring.  The  injection
s  monitored  for  about  5  minutes  within  a  region  of  interest
ROI)  appropriate  for  the  size  of  the  tumour.
To  evaluate  perfusion,  three  ROIs  of  identical  size  are
ositioned  at  a  site  of  marked  early  tumour  enhancement,
n  an  artery,  and  in  healthy  muscle,  respectively  [2].  Theime-intensity  curves  indicate  the  time  from  bolus  arrival
o  tumour  enhancement,  maximal  enhancement,  and  the
nhancement  slope  [5].  The  curves  can  be  classiﬁed  into
ve  types  (Fig.  1):
 type  1,  no  enhancement  (e.g.,  lipoma  or  haematoma);
 type  2,  faint  and  gradual  enhancement  (e.g.,  benign
tumours  or  schwannoma);
 type  3,  rapid  early  enhancement  followed  by  a  plateau
(limited  speciﬁcity  for  tumour  characterisation:  benign
vascular  tumours,  desmoid  tumours,  abscesses,  some
malignant  tumours);
 type  4,  rapid  early  enhancement  followed  by  a  washout
phase  (highly  vascular  tumours  with  a  small  intersti-
tial  compartment  including  several  malignant  tumours
[malignant  histiocytoﬁbroma,  synovial  cell  sarcoma,  and
leiomyosarcoma]  and  several  benign  tumours  [e.g.,  giant-
cell  tumour  and  osteoid  osteoma  nidus]);
type  5,  rapid  early  enhancement  followed  by  slow  grad-
ual  enhancement  (e.g.,  tumours  after  radiotherapy  or
chemotherapy  and  tumours  with  large  interstitial  com-
partments  such  as  myxoid  tumours).  A  colour  map  of
enhancement  parameters  can  be  produced.
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Characterisation  of  the  tumour  tissue
In  dynamic  imaging,  the  ﬁrst  pass  of  the  contrast  agent
serves  to  evaluate  tissue  vascularisation  and  tumour  per-
fusion  [1,6]. Enhancement  occurs  earlier  and  is  more  marked
in  tissues  characterised  by  an  abundant  vasculature  and  high
capillary  permeability  than  in  poorly  vascularised  tissues  [9].
However,  both  quantitative  and  qualitative  overlap  occurs
between  the  time-intensity  curves  of  highly  vascular  benign
tumours  and  those  of  poorly  vascularised  malignant  tumours
[1,6].
Staging  of  local  tumour  spread
A  detailed  clinical  and  radiological  assessment  of  local  and
general  tumour  spread  is  crucial  to  management  decisions
such  as  the  choice  of  the  biopsy  site  and  determination
of  the  tumour  resection  margins  [5].  The  initial  slopes
of  tumours  and  non-tumour  tissues  vary  widely  [10,11].
Dynamic  imaging  can  provide  a  more  accurate  determina-
tion  of  the  tumour  contours,  as  enhancement  occurs  earlier
in  the  tumour  tissue  than  in  the  surrounding  oedema.
Viable  tumour  sites
Identiﬁcation  of  well-vascularised  areas  of  viable  tumour  tis-
sue  is  crucial  to  select  the  biopsy  site.  This  step  ensures  that
the  biopsy  is  not  performed  at  sites  of  poorly  vascularised
tumour  tissue  with  oedema  and  necrosis  [1,5].
Chemotherapy  monitoring
An  accurate  evaluation  of  the  tumour  response  during
the  initial  treatment  phase  is  of  the  utmost  importance
to  assess  treatment  effectiveness,  plan  the  rest  of  the
treatment  strategy,  and  predict  the  outcome  [8].  The
quantitative  criterion  used  to  assess  the  effectiveness  of
preoperative  chemotherapy,  most  notably  in  patients  with
chemo-sensitive  tumours  of  bone  (e.g.,  osteosarcoma  and
Ewing’s  sarcoma)  and  soft  tissues  (e.g.,  synovial  cell  sar-
coma)  is  the  percentage  of  tumour  necrosis,  which  separates
responders  from  non-responders  [1].  During  follow-up  in
poor  responders,  the  time-intensity  curve  and  slope  value
increase,  remain  unchanged,  or  show  only  small  decreases
[1].  Changes  in  the  time-intensity  curve  with  an  at  least
60%  decrease  in  the  slope  value  indicate  more  than  90%  of
tumour  necrosis,  which  deﬁnes  a  good  treatment  response.
Dynamic  perfusion  MRI  makes  a  major  contribution  to
patient  follow-up  during  chemotherapy.  Its  diagnostic  accu-
racy  for  differentiating  good  and  poor  responders  has  ranged
from  85.7%  to  100%  [1,6]. Optimal  follow-up  requires  three
dynamic  perfusion  MRI  studies,  before  the  biopsy,  during
chemotherapy,  and  immediately  before  surgery,  respec-
tively  [1].
Detection  of  residual  or  recurrent  tumoursDynamic  perfusion  MRI  is  useful  for  detecting  viable  tumour
tissue  and  differentiating  it  from  reactive  tissue  changes
caused  by  the  treatment.  With  standard  MRI,  residual  or
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ecurrent  tumour  may  be  difﬁcult  to  distinguish  from  bone
arrow  reconversion,  inﬂammation,  or  reactive  ﬁbrosis
1].  During  dynamic  perfusion  MRI,  ﬁrst-pass  enhancement
ccurs  earlier  and  faster  in  residual  or  recurrent  tumour
issue  than  in  reactive  tissue  or  pseudo-tumours,  where
nhancement  occurs  later  and  more  slowly,  at  the  same  rate
s  in  healthy  muscle  [1,5].
roton  nuclear  magnetic  resonance  spectroscopy
roton  NMR  spectroscopy  can  be  used  to  characterise  the
olecules  present  in  malignant  musculoskeletal  tumours
3,12].  Proton  NMR  spectroscopy  is  more  widely  used  for
rain  imaging  [13]. The  lesions  are  characterised  based
n  their  metabolic  constituents,  such  as  choline,  a  phos-
holipid  found  in  the  cell  membrane  [11]. An  increased
roportion  of  choline  indicates  accelerated  cell-membrane
urnover,  which  is  an  indirect  marker  for  malignancy  [3,12].
he  in  vivo  choline/creatine  ratio  differentiates  malignant
xtra-cranial  head-and-neck  tumours  from  healthy  muscle.
roton  NMR  spectroscopy  has  been  used  in  bone  and  soft-
issue  tumours,  breast  cancer,  prostate  cancer,  and  cervical
ancer.  The  results  differentiate  malignant  from  benign
usculoskeletal  tumours  [3,12].
Proton  NMR  spectroscopy  results  can  be  translated  into
ixel  intensity  maps  based  on  the  relative  signal  from
he  metabolite  (water,  choline,  creatine,  and  lipids),  using
ulti-voxel  and  single-voxel  techniques.  Multi-voxel  proton
MR  spectroscopy  has  been  proved  feasible  for  charac-
erising  musculoskeletal  tumours  [12]. The  ROIs  must  be
ainstakingly  positioned  at  sites  of  early  marked  enhance-
ent  that  do  not  contain  bony  structures,  necrotic  or
aemorrhagic  foci,  calciﬁcations,  fat,  or  muscle.  For
umours  exhibiting  weak  and  slow  enhancement  or  no
nhancement  after  5  minutes,  the  voxel  is  positioned  at  sites
f  delayed  enhancement.
The  choline  peak  serves  to  differentiate  benign  and
alignant  tumours.  A  choline  peak  is  in  favour  of  a  malig-
ant  lesion  but  can  be  found  in  metabolically  active  benign
esions  and  in  abscesses  [3,13]. A  lipid  peak  is  usually  visible
n  abscess  walls,  solid  components  of  malignant  masses,  and
reated  tumours,  where  it  reﬂects  cell-membrane  turnover.
are  should  be  taken  to  avoid  peak  contamination  by
eighbouring  structures,  as  well  as  excessive  noise.
iffusion magnetic resonance imaging
iffusion  MRI  provides  quantitative  and  qualitative  assess-
ents  of  tissue  cellularity  and  cell-membrane  integrity.
t  is  widely  used  for  tumour  detection,  characterisation,
nd  monitoring  during  treatment.  Diffusion  MRI  supplies
unctional  information  that  complements  the  structural
valuation  [2].
Diffusion  MRI  measures  the  random  movements  of  water
olecules  in  the  body  (Brownian  motion).  Water  molecule
otion  is  assessed  in  vivo  in  the  extracellular,  intracellular,
nd  transcellular  compartments,  as  well  as  in  the  intravas-
ular  compartment  (microcirculation-perfusion)  [11]. Blood
ow  in  the  intravascular  compartment  leads  to  water
olecule  diffusion  over  longer  distances,  compared  to  the
xtracellular  and  intracellular  compartments.  The  contri-
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ution  of  intravascular  water-molecule  diffusion  to  the
iffusion  image  varies  across  tissues;  it  can  be  signiﬁcant  in
ighly  vascularised  tumours.  Restriction  of  water-molecule
iffusion  within  biological  tissues  correlates  negatively  with
issue  cellularity  and  membrane  integrity  [14]. Restriction  is
reater  in  highly  cellular  tissues  that  have  intact  cell  mem-
ranes  and  a  small  extracellular  compartment.
Tumours  differ  regarding  their  cellular  characteristics,
nd  the  differences  can  serve  to  differentiate  tumour
ypes.  Cellularity  is  greater  in  malignant  tumours,  in  which
estriction  of  water-molecule  diffusion  tends  to  be  greater,
ompared  to  benign  tumours  [2,15].
ualitative  diffusion  magnetic  resonance  imaging
iffusion  MRI  is  performed  using  a  conventional  T2-weighted
equence  with  diffusion  gradients  to  ﬁlter  the  signal  from
ighly  mobile  water  molecules  and  to  improve  the  detec-
ion  of  diffusion  and  mobility.  Available  diffusion  sequences
nclude  spin  echo  diffusion-weighted  imaging  (DWI),  echo-
lanar  imaging  (EPI),  and  steady-state  free  precession  (SSFP)
maging  [11]. EPI  has  a  short  acquisition  time  and  is  conse-
uently  the  most  widely  used  sequence,  with  a  single-shot  or
ulti-shot  technique.  To  improve  interpretation  accuracy,
t  least  two  different  b  values  are  generally  used  (0  and  600
r  1000  s/mm2).  The  b  value  reﬂects  the  diffusion  force  and
iffusion  weighting  of  the  image,  just  as  the  echo  time  (TE)
eﬂects  T2  weighting  of  T2  images  [2,11]. Cystic  tumours
xhibit  greater  signal  attenuation  on  high  b-value  images,
eﬂecting  the  smaller  degree  of  water-molecule  motion
estriction,  whereas  solid  masses  and  cellular  tumours  con-
inue  to  generate  a  high-intensity  signal.uantitative  diffusion  imaging
iffusion  MRI  with  multiple  b  values  provides  a  quantita-
ive  analysis  via  the  apparent  diffusion  coefﬁcient  (ADC).
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igure  2  High-grade  synovial  cell  sarcoma  of  the  left  knee  (arrow
ignal intensity  that  rules  out  a  predominant  myxoid  component  (b
ow mean  ADC  of  0.81  × 10−3 mm2/s  suggesting  a  malignancy.J.-L.  Drapé
DC is  an  exponential  function  of  the  tumour  signal  on  the
mages  acquired  with  different  b  values.  The  ADC  is  com-
uted  for  each  pixel  of  the  image,  and  a  map  of  the  ADC
alues  is  created.  Tissues  can  be  differentiated  by  using
OIs  on  the  ADC  map.  Highly  cellular  sites  with  restricted
iffusion  have  lower  ADC  values  compared  to  sites  charac-
erised  by  lower  cell  densities.  Sites  with  low  ADC  values
enerate  higher  signal  intensity  on  diffusion  images.  How-
ver,  the  ADC  depends  not  only  on  water-molecule  diffusion
n  the  extracellular  tumour  compartment,  but  also  on  the
egree  of  tumour  perfusion  [15]. The  perfusion  fraction
microcirculation)  in  malignant  soft-tissue  tumours  tends  to
e  greater  and  to  make  a  larger  contribution  to  ADC  ele-
ation  than  in  benign  soft-tissue  tumours.  Thus,  perfusion
an  produce  a  larger  ADC  increase  in  malignant  tumours,
eading  to  overlap  between  ADC  values  of  malignant  and
enign  tumours  [2].  Diffusion  images  corrected  for  perfusion
perfusion-insensitive  ADC  value,  PIADC)  limit  the  impact  of
his  effect  [15]. Conventional  ADC  values  are  measured  with
 values  of  0  and  600  s/mm2. Water  molecules  that  move
reely  and  diffuse  over  long  distances  (e.g.,  in  the  intravas-
ular  compartment)  show  signal  attenuation  at  low  b  values
50—100  s/mm2).  In  contrast,  water  molecules  that  move
lowly  or  diffuse  over  short  distances  exhibit  more  gradual
ignal  attenuation  with  increasing  b  values  (1000  s/mm2).
umour  cellularity  correlates  linearly  with  the  minimum
DC  value  (Pearson  coefﬁcient,  −0.88),  and  high-grade
esions  tend  to  produce  lower  values  [16]. However,  benign
on-myxoid  tumours  have  a  higher  mean  ADC  value  com-
ared  to  malignant  lesions  (1.31  ±  0.46  ×  10−3 mm2/s  versus
.94  ±  0.25  ×  10−3 mm2/s,  P  <  0.001)  (Fig.  2)  [17]. In  com-
ination  with  standard  structural  MRI  parameters,  the  ADC
alue  improves  tumour  characterisation  [18].
Diffusion  MRI  can  also  be  used  to  monitor  tumours
uring  chemotherapy.  Tumour  necrosis  results  in  loss  of  cell-
embrane  integrity  and  in  expansion  of  the  extracellular
ompartment,  leading  to  greater  water-molecule  diffusion
ith  an  increase  in  the  ADC  value  [2].
s).  (a)  Coronal  section,  T2  FS  (TR  6230/TE  160  ms):  moderate
)  apparent  diffusion  coefﬁcient  (ADC)  map  (b  =  0—600  s/mm2):
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Figure  3  Osteoid  osteoma  (a)  coronal  section,  T1  with  gadolinium  injection  and  fat  saturation:  cortical  hyperostosis  of  the  lesser
ns  o
s.
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arterial structure  (2);  c:  type  3  time-intensity  curve  at  the  nidu
In-phase and opposed-phase imaging
Chemical  shift  imaging  relies  on  the  lipid/water  ratio  in  a
given  tissue  voxel.  This  imaging  modality  can  differentiate
malignant  from  benign  tumours  and  is  widely  used  to  eval-
uate  tumours  of  the  liver  and  adrenal  glands  [19,20].  It  can
also  be  applied  to  bone  tumours.  Signal  changes  between
in-phase  images  (TE  =  4.6  ms)  and  opposed-phase  images
(TE  =  2.4  ms)  differ  between  tumours  and  non-neoplastic
lesions  of  the  spine  [21]. Chemical  shift  imaging  is  indicated
to  differentiate  a  crush  fracture  due  to  a  tumour  from  an
acute  mechanical  crush  fracture.  Another  possible  use  is  the
monitoring  of  tumours  during  treatment  [20].
The  bone  marrow  has  high  fat  and  water  contents,  but
the  differences  in  the  amounts  of  fat  and  water  produce
the  bone  signal  during  MRI  [21]. The  simultaneous  presence
of  fat  and  water  in  the  normal  marrow  results  in  signal
suppression  on  opposed-phase  images.  Inﬁltration  of  the
bone  marrow  by  the  tumour  completely  replaces  the  fat
component,  leading  to  loss  of  signal  suppression  on  opposed-
phase  images  [19,20].  Water  and  fat  protons  have  different
precession  frequencies,  reﬂecting  the  differences  in  their
environments.  ROIs  can  be  positioned  in  doubtful  areas  and
the  ratio  of  the  bone-marrow  signal  intensities  on  the  two
images  computed.  A  cut-off  value  of  0.8  has  been  suggested,
with  higher  values  indicating  a  tumour  and  lower  values  a
non-neoplastic  lesion  [20,21].
Clinical applications
We  will  use  a  few  examples  to  illustrate  the  contribution  of
advanced  MRI  techniques  to  the  evaluation  of  musculoskele-
tal  tumours.Osteoid  osteoma
In  most  patients,  radiographs,  computed  tomography,  and
bone  scintigraphy  are  sufﬁcient  to  establish  the  diagnosis  by
A
l
w
cf  interest  positioned  on  the  presumptive  nidus  (1)  and  on  an
isualising  a  nidus  with  a  variable  degree  of  calciﬁcation,  a
urrounding  rim  of  sclerosis,  and  cortical  thickening  [22]. At
ome  sites,  however,  the  diagnosis  may  be  challenging.  MRI
vidence  of  oedema  surrounding  the  tumour  is  suggestive
ut  may  mask  the  nidus  in  some  cases.  The  vascular  groove
ign  around  the  nidus  lacks  sensitivity  but  is  highly  speciﬁc
or  differentiating  an  osteoid  osteoma  from  another  lesion
y  CT.  Although  MRI  is  classically  considered  less  informative
or  detecting  the  nidus,  dynamic  perfusion  MRI  may  be  help-
ul  [22,23].  Enhancement  maps  can  distinguish  an  osteoid
steoma  from  an  infection  (Brodie  abscess),  synovitis,  and
ther  tumour  types.  Most  osteoid  osteomas  exhibit  arterial
nhancement  followed  by  rapid  partial  washout,  reﬂecting
he  marked  vascularisation  of  the  nidus  (Fig.  3).  Dynamic
D  sequences  with  thin  sections  and  no  gap  can  be  used  to
onitor  the  injection  and  to  produce  an  enhancement  map.
Chemical  shift  imaging  may  also  be  useful  in  this  indica-
ion.  The  ratio  of  opposed-phase  and  in-phase  nidus  signals  is
reater  than  1  (from  1.04  to  1.26),  whereas  the  surrounding
issue  has  a  low  ratio  of  0.36  on  average.
bscesses,  hematomas,  and  necrotic  tumours
 deﬁnite  diagnosis  of  abscess  modiﬁes  the  management
trategy,  as  drainage  is  in  order.  Abscesses  may  have  a  rich
lood  supply  with  perfusion  slopes  similar  to  those  seen
n  malignant  tumours  [6].  On  the  other  hand,  malignant
umours  exhibiting  extensive  necrosis  may  have  low  slope
alues  similar  to  those  seen  in  benign  tumours  [6].  In  addi-
ion,  benign  lesions  that  contain  inﬂammatory  cells,  such  as
bscesses,  can  produce  choline  peaks  despite  the  absence
f  malignant  transformation.
Diffusion  MRI  of  brain  abscesses  typically  shows  a  marked
eduction  of  the  ADC  value  in  the  necrotic  core  [2].
bscesses  contain  inﬂammatory  cells,  a  protein  matrix,  cel-
ular  debris,  and  bacteria  within  highly  viscous  pus,  limiting
ater-molecule  mobility.  Therefore,  the  abscess  cavity  is
haracterised  by  high  signal  during  diffusion  MRI,  with  a  low
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DC  value.  Diffusion  tends  to  be  greater  in  the  necrotic  part
f  necrotised  tumours  than  in  abscesses.  The  ADC  map  shows
 greater  degree  of  diffusion  restriction  in  the  solid  part  of
ggressive  malignancies  [2].
Differentiating  a  haematoma  from  a  haemorrhagic
alignant  tumour  may  be  challenging  [2].  Diffusion
RI  can  differentiate  a  growing  chronic  haematoma
rom  a  malignant  tumour.  The  mean  ADC  value  is
igniﬁcantly  higher  in  haematomas  than  in  soft-
issue  malignancies  (1.55  ±  0.121  ×  10−3 mm2/s  versus
.92  ±  0.139  ×  10−3 mm2/s,  P  <  0.01).  Acute  and  subacute
aematomas  produce  characteristic  MRI  features,  and
he  ADC  map  shows  restricted  diffusion  in  the  centre
f  the  lesion.  Contrast  enhancement  is  rare  in  benign
aematomas.  Haemoglobin  breakdown  products  complicate
he  NMR  spectroscopy  analysis  of  haematomas.  Neverthe-
ess,  haemorrhagic  malignancies  tend  to  produce  a  choline
eak  in  the  solid  part  of  the  tumour,  reﬂecting  active  cell
ivision.
yxoid  tumours
yxoid  tissue  is  found  in  myxoma,  myxoid  liposar-
oma,  and  myxoid  malignant  ﬁbrous  histiocytoma  [1].
DC  values  are  higher  in  malignant  and  non-malignant
yxoid  soft-tissue  tumours  than  in  non-myxoid  tumours
2.08  ±  0.51  ×  10−3 mm2/s  versus  1.13  ±  0.40  ×  10−3 mm2/s,
 <  0.001)  [2,15]. The  high  ADC  values  are  related  to  the
igh  mucin  and  low  collagen  contents  of  these  water-rich
esions  [2].  The  presence  of  a  myxoid  component  results  in
onsiderable  overlap  between  the  ADC  values  of  benign  and
alignant  myxoid  tumours.
Myxoid  liposarcoma  is  a  malignant  fatty  tumour  that
ccounts  for  one-third  of  all  liposarcomas.  The  low-intensity
ignal  on  T1  images  and  high-intensity  signal  on  T2  images
ay  suggest  a  cyst.  Myxoid  liposarcoma  may  be  indis-
inguishable  from  most  benign  and  malignant  soft-tissue
umours  [1,2]. Perfusion  techniques  are  useful  for  dis-
inguishing  cysts  from  myxoid  tumours:  cysts  show  no
nhancement,  whereas  the  myxoid  component  of  sarcomas
xhibit  marked  and  rapid  enhancement  [1].
Intramuscular  myxoma  is  a  benign  tumour  characterised
y  an  abundant  myxoid  stroma  and  the  virtual  absence
f  blood  vessels.  Nevertheless,  enhancement  occurs  dur-
ng  perfusion  imaging,  albeit  in  a  gradual  fashion.  Tumour
lling  occurs  gradually  over  the  ﬁrst  few  minutes  after  the
olus  injection,  because  of  both  the  large  interstitial  com-
onent  and  the  low  perfusion  rate  [1].  Rapid  ﬁlling  of  a
yxoid  tumour  should  suggest  a  malignancy  such  as  a  myx-
id  liposarcoma  or  synovial  cell  sarcoma.  A  comparison  of
he  structural  data  from  conventional  MRI  and  of  the  per-
usion  and  diffusion  MRI  data  improves  diagnostic  accuracy
n  myxoid  tumours  [2].
esions  of  the  cartilage
istinguishing  an  enchondroma  from  a  low-grade  chon-
rosarcoma  is  crucial  to  select  the  treatment  strategy.
adiographs,  CT,  and  even  standard  MRI  cannot  easily  dis-
inguish  these  two  lesions,  and  neither  is  bone  scintigraphy
eliable  [1].  The  use  of  dynamic  perfusion  MRI  has  been
o
r
i
[J.-L.  Drapé
uggested  as  a  means  of  distinguishing  low-grade  chon-
rosarcoma  and  active  enchondroma  from  inactive  enchon-
roma.  Inactive  enchondroma  is  characterised  by  limited
nhancement  and  perfusion,  contrasting  with  the  early  rapid
nhancement  of  both  active  enchondroma  and  chondrosar-
oma  [1].  Perfusion  MRI  cannot  distinguish  these  last  two
esions.
Malignant  tumours  of  cartilage  can  exhibit  higher  ADC
alues  than  benign  tumours  [2].  In  both  benign  and  malig-
ant  tumours,  high  ADC  values  are  due  to  the  chondroid
atrix.  Further  studies  are  needed  to  determine  the  contri-
ution  of  diffusion  MRI  to  the  evaluation  of  cartilage
esions.
steosarcoma  and  Ewing’s  sarcoma
steosarcoma  and  Ewing’s  sarcoma  account  for  over  90%
f  all  primary  bone  tumours  in  children.  Chemotherapy  is
sually  given  before  surgery  is  performed.  An  accurate  eval-
ation  of  the  tumour  response  to  the  initial  chemotherapy
hase  is  valuable  for  adjusting  the  treatment  regimen  and
redicting  the  outcome  [8].  Histological  examination  of  the
perative  specimen  is  the  reference  standard  for  evaluat-
ng  the  treatment  response.  In  good  responders,  more  than
0%  of  the  tumour  tissue  is  necrotic.  Survival  is  consider-
bly  longer  in  good  responders  than  in  poor  responders.
tandard  contrast-enhanced  MRI  cannot  provide  an  evalu-
tion  of  the  extent  of  the  necrosis  [1].  Both  viable  tissue
nd  necrotic  tissue  generate  high  signal  on  T2  images.
hemotherapy  can  cause  bleeding,  necrosis,  oedema,  and
ypervascular  ﬁbrosis  with  no  distinctive  features  by  MRI
2,6,8].  In  addition,  effective  chemotherapy  usually  fails
o  shrink  osteosarcomas,  since  there  is  little  effect  on  the
ineralised  tumour  matrix.  Studies  of  enhancement  curves
how  that  a  greater  than  60%  decrease  in  slope  value  at
he  sites  of  maximal  slope  before  chemotherapy  is  the
est  marker  for  a  good  treatment  response  [8].  This  tech-
ique  is  sufﬁciently  speciﬁc  only  when  used  at  least  4  to
 weeks  after  chemotherapy  initiation.  Poorly  vascularised
umour  tissue,  such  as  chemotherapy-resistant  chondroblas-
ic  foci  of  osteosarcomas,  may  mimic  tumour  necrosis.  On
he  other  hand,  foci  of  granulation  tissue  replacing  necrotic
umour  tissue  may  mimic  viable  tumour  tissue.  The  dynamic
tudy  is  best  performed  3  months  after  chemotherapy  ini-
iation,  when  the  granulation  tissue  has  decreased  but  the
esidual  tumour  tissue  is  still  abundantly  vascularised  and
erfused.
By  diffusion  MRI,  the  ADC  values  of  viable  tumour
issue  and  necrotic  tumour  tissue  differ  considerably.  There-
ore,  diffusion  MRI  can  be  used  to  assess  the  treatment
esponse.  This  technique  can  detect  earlier  modiﬁcations,
s  changes  at  the  cell  level  precede  gross  tumour  shrink-
ge.  Diffusion  MRI  visualises  highly  cellular  foci  in  the
egions  that  have  been  altered  by  the  treatment  [24].
n  osteosarcomas,  treatment-induced  ADC  changes  corre-
ate  directly  with  the  extent  of  tumour  necrosis  (Fig.  4).
he  minimal  ADC  values  of  the  solid  components  of
steosarcomas  differ  signiﬁcantly  between  good  and  poor
esponders  [25]. Diffusion  MRI  is  emerging  as  a  promis-
ng  tool  for  monitoring  the  treatment  of  osteosarcoma
2,25].
Advances  in  magnetic  resonance  imaging  of  musculoskeletal  tumours  S121
Figure  4  Osteosarcoma  of  the  right  femur.  MRI  after  chemotherapy  and  before  surgery.  (a)  sagittal  section,  STIR  sequence:  het-
erogeneous signals  from  ill-deﬁned  necrotic  foci  (b)  apparent  diffusion  coefﬁcient  (ADC)  map  (b  =  0—600  s/mm2):  marked  elevation
of the  minimum  ADC  value  (2.13  ×  10−3 mm2/s)  in  the  necrotic  foci  compared  to  the  minimum  ADC  value  ion  the  residual  tumour
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Miscellaneous  malignant  bone  tumours  —  vertebral
crush fractures
Diffusion  MRI  of  a  body  site  or  the  whole  body  used  in  com-
bination  with  conventional  MRI  has  considerable  diagnostic
value  for  detecting  bone  metastases.  Compared  to  positron-
emission  tomography  (PET)  and  bone  scintigraphy,  diffusion
MRI  detects  a  larger  number  of  metastases,  as  well  as  metas-
tases  of  smaller  size  [26]. Bone  metastasis  detection  is
crucial  for  cancer  staging  and  for  selecting  the  treatment
strategy.
Acute  vertebral  crush  fracture  is  a  common  clinical  prob-
lem  in  elderly  individuals  and  is  often  due  to  osteoporosis  or
metastatic  bone  disease.  In  difﬁcult  cases,  to  avoid  having
to  perform  a  percutaneous  bone  biopsy,  monitoring  by  MRI
(gradual  fat  signal  recovery  in  the  event  of  a  mechanical
crush  fracture)  or  positron-emission  tomography/computed
tomography  may  be  helpful.  Crush  fractures  due  to  tumours
are  characterised  by  increased  ﬂuorodeoxyglucose  (FDG)
uptake.  MRI  evaluation  of  the  peak  and  ﬁrst-pass  enhance-
ment  slope  in  the  vertebral  bodies  shows  that  a  type  4  curve
with  rapid  enhancement  followed  by  a  washout  phase  has
high  positive  predictive  value  (PPV)  for  a  bone  metasta-
sis.  A  type  5  curve  with  rapid  enhancement  then  a  second
phase  of  weaker  enhancement  has  high  PPV  for  a  benign
crush  fracture.  In-phase  and  opposed-phase  imaging  can  also
be  useful  for  differentiating  benign  and  metastatic  crush
fractures.  For  the  signal-intensity  decrease  on  the  opposed-
phase  image  compared  to  the  in-phase  image,  35%  is  the
cut-off  for  differentiating  the  two  lesions.  This  cut-off  can
also  serve  as  an  early  marker  for  the  response  to  spinal
radiotherapy.Proton  NMR  spectroscopy  is  also  useful,  since  a  choline
peak  suggests  a  malignant  crush  fracture  [12]. Qualita-
tive  and  quantitative  diffusion  imaging  improves  diagnostic
speciﬁcity  [11].
s
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cA high-intensity  signal  by  diffusion  MRI  suggests  a  malig-
ant  crush  fracture  [27]. Image  quality  is  best  with  low
 values.  With  a  b  value  of  about  300  s/mm2, fractional
nisotropy  (FA)  is  signiﬁcantly  diminished  in  the  event  of
 neoplastic  crush  fracture.  Lower  b  values  have  no  dis-
riminating  potential  [28]  and  higher  b  values  have  the
isadvantage  of  decreasing  the  signal-to-noise  ratio.
onitoring  the  treatment  response
iffusion  MRI  can  also  be  used  to  estimate  residual  tumour
ctivity  after  treatment  and  to  detect  recurrences  at  an
arly  stage  when  curative  treatment  is  still  possible.  Dif-
erentiating  treatment-related  tissue  changes  from  residual
r  recurrent  tumour  tissue  is  a  common  problem,  given  the
ack  of  speciﬁcity  of  the  signal  abnormalities  by  standard  MRI
low  signal  on  T1  images  and  high  signal  on  T2  images).  Dif-
usion  shows  larger  increases  in  foci  of  treatment-related
umour  necrosis  than  in  viable  tumour  recurrences  [28].
olid  tumours  are  characterised  by  high  cellularity  and
ntact  cell  membranes,  contrasting  with  the  lower  cellular-
ty  and  membrane  damage  seen  in  treatment-altered  tissues
29]. Necrosis  of  osteosarcomas  results  in  elevated  ADC  val-
es  [30]. Both  the  minimum  and  the  mean  ADC  values  of
steosarcomas  are  signiﬁcantly  increased  after  chemother-
py,  compared  to  baseline.  The  minimum  ADC  value  is  even
igniﬁcantly  higher  in  good  responders  (more  than  90%  of
ecrosis  by  histological  examination)  than  in  poor  respon-
ers  (1.01  ±  0.22  versus  0.5  ±  0.29,  P  <  0.05)  (Fig.  5)  [30].
Dynamic  perfusion  MRI  is  the  method  of  choice  for  esti-
ating  the  response  to  preoperative  chemotherapy.  Good
nd  poor  responders  can  be  separated  based  on  the  ﬁrst-pass
ubtraction  images  or  enhancement  time-intensity  curves.
ecurrent  bone  tumours  (with  the  exception  of  the  carti-
age  components)  exhibit  earlier  and  faster  enhancement
ompared  to  the  reference  tissue  (healthy  muscle)  [1].
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Figure  5  Osteosarcoma  of  the  left  femur.  Follow-up  MRI  after  three  chemotherapy  courses.  a:  axial  section,  STIR  sequence
(TR/TI/TE 5520/160/60  ms):  the  tissue  necrosis  is  difﬁcult  to  evaluate  (arrows).  Tumour  spread  to  the  intercondylar  notch  (*);  b:
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Rpparent diffusion  coefﬁcient  (ADC)  map  (b  =  0—600  s/mm2):  th
light increase  compared  to  the  baseline  value  of  0.64  ×  10−3 m
In  soft-tissue  sarcomas,  the  foci  of  early  and  rapidly  pro-
ressive  enhancement  are  composed  of  residual  or  recurrent
umour,  whereas  absence  of  early  enhancement  indicates  a
ood  response.  Radiotherapy  may  lead  to  neovascularisation
ith  increased  perfusion.  A  reaction  containing  granulation
issue  may  be  difﬁcult  to  distinguish  from  tumour  tissue
uring  the  ﬁrst  3  to  6  months  after  radiotherapy.  Monitor-
ng  is  indispensable  in  this  situation:  over  time,  perfusion
ecreases  within  reactive  masses  but  increases  in  tumour
issue,  which  is  richly  vascularised.
onclusion
dvanced  MRI  techniques  complement  standard  MRI  but
emain  insufﬁciently  used.  They  delineate  tissue  hetero-
eneity  with  greater  speciﬁcity  and  therefore  help  to  guide
he  biopsy.  Advanced  MRI  techniques  also  provide  an  early
valuation  of  good  responders  and  ensure  the  detection  of
esidual  or  recurrent  tumour.
In  cases  that  remain  doubtful  despite  standard  MRI,  a
hoice  must  be  made  in  clinical  practice  among  the  many
vailable  advanced  techniques:
 atypical  osteoid  osteoma:  dynamic  perfusion  MRI  with
gadolinium  injection  and  enhancement  time-intensity
curves;
tumour  haematoma  (?):  diffusion  MRI;
 vertebral  crush  fracture  due  to  a  tumour  or  to  osteoporo-
sis  (?):  diffusion  MRI  with  determination  of  the  ADC,  with
in-phase  and  opposed-phase  imaging;
treatment  response  in  soft-tissue  sarcomas:
◦ a  recurrent  mass  generating  high  signal  on  T2  imagesdoes  not  require  complementary  functional  MRI  tech-
niques,
◦  in  the  event  of  marked  oedema  on  T2  images  with
no  well-deﬁned  mass,  dynamic  perfusion  MRI  withnimum  ADC  value  remains  low,  at  0.72  ×  10−3 mm2/s  despite  a
.  These  ﬁndings  suggest  a  poor  treatment  response.
gadolinium  injection  and  enhancement  time-intensity
curves  and/or  diffusion  MRI;
 early  osteosarcoma  response  to  chemotherapy:  dynamic
perfusion  MRI  with  gadolinium  injection  and  enhancement
time-intensity  curves;  diffusion  imaging  is  being  evalu-
ated  in  this  situation.
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